Printer Friendly

A Novel Null Mutation in P450 Aromatase Gene (CYP19A1) Associated with Development of Hypoplastic Ovaries in Humans.


Aromatase deficiency can cause various clinical phenotypes resulting from excessive androgen accumulation and insufficient estrogen synthesis. Aromatase deficiency has been reported to cause delayed puberty in adolescent girls, minimal or absent breast development, primary amenorrhea, hypergonadotropic hypogonadism, tall stature, delayed bone age, and enlarged and multicystic ovaries.


A novel insertion mutation in the aromatase gene (CYP19A1) was found which caused a frameshift in the open reading frame and a truncation of the protein prior to the heme-binding region. Homozygosity for this mutation was associated with the development of hypoplastic ovaries. This finding provides an important genetic marker for understanding the physiological function of aromatase in fetal ovarian development.


Aromatase (CYP19A1) catalyzes the conversion of androgens to estrogens, which is a key step in estrogen biosynthesis (1,2). The enzyme is mainly located in the endoplasmic reticulum of estrogen-producing cells in the ovary, placenta, testis, brain, adipose tissue, liver, muscle, and hair follicles (3,4). During pregnancy, dehydroepiandrosterone sulfate (DHEAS) and 16OH-DHEAS, arising from the fetal adrenal gland and liver, respectively, become important sources for the synthesis of placental estrogens (4,5). To date, more than eleven genetic mutations in CYP19A1 gene have been reported in multiple studies with in vivo phenotype information (6,7,8,9,10,11,12,13,14). Placental aromatization of androgens has been suggested to be essential for protecting both the mother and any female fetus against the virilizing action of fetal androgens, particularly during differentiation of external genitalia (4). Autosomal recessive mutations in the CYP19A1 gene have been reported to cause disorders of sex development (DSD) and virilization of the mother during pregnancy (11,12,13,15). Here, we report the clinical and genetic features of three cousins with a novel homozygous mutation (568insC) in CYP19A1 that caused severe aromatase deficiency. The present study suggests that severe aromatase deficiency appears to be associated with hypoplastic rather than enlarged and multicystic ovaries.


Study Subjects

Case 1 (index case, IV3) was a Turkish female presenting with clitoromegaly and partial labial fusion at birth (Prader II), the third child of consanguineous parents (Figure 1). A history of voice changes and hirsutism in the mother during pregnancy was reported. The mother was also reported to demonstrate symptoms of hemolysis, elevated liver enzymes, low platelet count (HELLP) syndrome, and she died during labor. The infant was then hospitalized due to hypoxic-ischemic encephalopathy (HIE) and neonatal sepsis. Laboratory evaluation revealed hyperandrogenism without adrenal insufficiency The karyotype was 46,XX. After discharge from the hospital, she was again admitted at 7 years of age. At this time, the girl was found to have severe cerebral palsy and failure to thrive [height: 103 cm, -3.6 standard deviation score (SDS); weight: 13 kg, -1.7 SDS]. She had no breast or pubic hair development but was noted to have clitoromegaly (1.5 cm). Pelvic ultrasonography (US) revealed a 26-mm uterus with hypoplastic ovaries (0.02 mL). Laboratory evaluation revealed normal androgen and basal gonadotropin levels with undetectable estradiol (Table 1).

Case 2 (IV6) was a Turkish female presenting with clitoromegaly, complete labial fusion, and single urogenital sinus at birth (Prader III). She was a cousin of case 1 and the third child of consanguineous parents (Figure 1). A history of maternal voice changes, acne formation, and clitoromegaly during pregnancy was reported. Laboratory evaluation revealed hyperandrogenism without adrenal insufficiency. The karyotype was 46,XX. The patient underwent vaginoplasty. At her last visit, at 5 years of age, she had mild clitoromegaly (1 cm) without any other clinical signs of hyperandrogenism. Pelvic US revealed a 23-mm uterus with hypoplastic ovaries (0.06 mL). Laboratory evaluation revealed normal androgen and high basal gonadotropin levels with undetectable estradiol (Table 1).

Case 3 (IV.1) was a cousin of case 2 and presented with clitoromegaly, complete labial fusion, and single urogenital sinus at birth (Prader III) (Figure 1). A history of maternal voice changes and acne formation during pregnancy was reported. Laboratory evaluation revealed hyperandrogenism without adrenal insufficiency. The karyotype was 46,XX. Vaginoplasty was performed. At her last visit, at 2.2 years of age, she had clitoromegaly (1.5 cm) without any other clinical sign of hyperandrogenism. Pelvic magnetic resonance imaging revealed a rudimentary uterus (11 mm) with hypoplastic ovaries (0.04 mL). Laboratory evaluation revealed normal androgen and high basal gonadotropin levels with normal estradiol (Table 1).

The subjects were interviewed carefully to determine their lineage and birth and were considered to belong to a pedigree. After explanation of the study, written informed consent was obtained from all participants before obtaining blood samples. DNA could not be isolated from other siblings due to socioeconomic reasons and parental non-compliance. However, according to the parents, those female siblings were healthy and had no clitoromegaly.

Sequencing and Identification of CYP19A1 Variants

Genomic DNA was isolated from peripheral whole blood using a QiAamp blood kit (Qiagen, Valencia, CA, USA). The research protocol for the use of human DNA was approved by the institutional review board of Busan Paik Hospital, Busan, Korea, and conformed to institutional guidelines (16). The exons, intron-exon junctions, promoter region, and 3'-untranslated region of CYP19A1 were polymerase chain reaction (PCR)-amplified and directly sequenced. Primers for PCR amplification and DNA sequencing were identical to those used previously (16).

Genetic Analysis of CYP19A1 Variants

Haploview 4.2 population genetic analysis software ( was used to analyze linkage disequilibrium (LD) and haplotype diversity. The sequence analysis programs NNSPLICE 0.9 ( and TFSEARCH ( were used to predict alternative splice sites and transcription factor-binding changes introduced by mutations, respectively.


Direct DNA sequencing analysis of the CYP19A1 gene in all subjects (n=8) revealed a total of 12 genetic variants. A summary of the identified variants is presented in Table 2. Among these 12 variations, a 568Cins in exon 5 was previously unidentified. The 568Cins was found as a heterozygous mutation in parents and a homozygous mutation in the three probands (Figure 2A). This insertion mutation caused a change of amino acid 190Leu to 190Pro and the subsequent frameshift was predicted to generate a stop codon, resulting in a truncated protein of 199 amino acids rather than the full functional 503 amino acids of the CYP19A1 protein (Figure 2B). No particular linkage was found with this novel mutation. None of variants were predicted to create or disrupt splice sites or transcription factor-binding elements.


Aromatase deficiency causes virilization of the mother during pregnancy and ambiguous genitalia of the female fetus due to prenatal exposure to adrenal androgens. In the postpartum period, some clinical features of androgen excess regress and elevated androgen concentrations return to normal levels. Aromatase deficiency has been reported to cause delayed puberty in adolescent girls, minimal or absent breast development, primary amenorrhea, hypergonadotropic hypogonadism, tall stature, delayed bone age, decreased bone mineral density, and multicystic ovaries (8,9). Additionally, it has been speculated that in aromatase-deficient prepubertal girls, an amplification of follicle-stimulating hormone (FSH) signaling might occur in the presence of high intraovarian androgen production and be responsible for the development of ovarian follicular cysts (4). However, affected male infants have normal internal and external genital development. Affected males have usually been diagnosed after puberty with tall stature, delayed bone age, decreased bone mineral density, and infertility (14). Interestingly, in our cases, the ovaries were hypoplastic without cyst formation. Luteinizing hormone (LH) and especially FSH levels were high at the final visits in cases 2 and 3 but not in case 1. Prepubertal levels of LH and FSH in case 1 may have been due to hypogonadotropic hypogonadism resulting from severe HIE during the neonatal period. Hypoplastic ovaries rather than enlarged ovaries in aromatase-deficient females have rarely been reported. There are only two cases with similar phenotype reported in the literature. Lin et al (12) reported a case of aromatase deficiency with hypoplastic ovaries and uterus. Karyotype was 46,XX. The patient had a severe mutation (exon5del) in exon 5 of the CYP19A1 gene, generating a truncated protein without the heme-binding region crucial for enzymatic activity. Recently, another case of severe aromatase deficiency due to a 27-base duplication in exon 8 has been reported (17). The case was a 25-year-old woman with delayed puberty and osteoporosis. She had a hypoplastic uterus and bilateral streak ovaries with 46,XX karyotype. The authors concluded that the streak ovaries may be an inherent manifestation of CYP19A1 deficiency. These two cases, similar to the present cases, exhibited a severe phenotype with clitoromegaly, labial fusion, and/or single urogenital sinus at birth.

Indeed, as the studies of CYP19A1 knockout (ArKO) mouse model have shown, follicular development in ovaries of ArKO is abnormal in an age-dependent manner, with an early block in follicular development at the antral stage with absent corpora lutea. Then, haemorrhagic cysts with absent secondary and antral follicles and atresia of primary follicles with increased collagen deposition are observed. Additionally, in the ArKO mouse, uterine weight was found to be very low compared to that of wild-type, possibly because of hypoestrogenism (18). These findings are consistent with those reported in the CYP19A1 knockout mouse.

Taking into consideration all these reports, we speculate that severe aromatase deficiency in intrauterine life can cause insufficient production of fetal estrogens in the human fetus as well as testosterone excess which in turn might result in maldevelopment of the fetal ovaries. However, it is obvious that not all patients with severe aromatase deficiency have hypoplastic ovaries. This can be explained by the fact that gonadal development is a multifactorial process and involves many genes that interact with each other Further in vitro and in vivo studies are necessary to understand this complex process.

In conclusion, a novel genetic variant in CYP19A1 gene was found to generate a null mutation. We suggest that severe aromatase deficiency caused by 568insC mutation can result in maldevelopment of ovaries in female fetuses. Further studies in large numbers of subjects would be necessary to understand the effect of this mutation on cancer, osteoporosis, and ovarian development.


This work was supported by the Korea Science and Engineering Foundation (KOSEF), funded by the Ministry of Education, Science, and Engineering (MOEST) (No. R13-2007-023-00000-0).


Ethics Committee Approval: Institutional Review Board of Busan Paik Hospital, Informed Consent: It was taken.

Peer-review: Internal peer-reviewed.

Authorship Contributions

Concept: Sema Akgurin, Doga Turkkahraman, Design: Sema Akgurin, Doga Turkkahraman, Su-Jun Lee, Data Collection and/or Processing: Doga Turkkahraman, Erdem Durmaz, Analysis and/or Interpretation: Woo-Young Kim, Erdem Durmaz, Jae-Gook Shin, Su-Jun Lee, Literature Research: Doga Turkkahraman, Erdem Durmaz, Writing: Doga Turkkahraman, Su-Jun Lee.

Financial Disclosure: The authors declared that this study received no financial support.


(1.) Nelson DR, Koymans L, Kamataki T Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, Gunsalus IC, Nebert DW. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996;6:1-42.

(2.) Means GD, Mahendroo MS, Corbin CJ, Mathis JM, Powell FE, Mendelson CR, Simpson ER. Structural analysis of the gene encoding human aromatase cytochrome P-450, the enzyme responsible for estrogen biosynthesis. J BiolChem 1989;264:19385-19391.

(3.) McNatty KP Makris A, DeGrazia C, Osathanondh R, Ryan KJ. The production of progesterone, androgens, and estrogens by granulosa cells, theca tissue and stromal tissue from human ovaries in vitro. J Clin Endocr Metab 1979;49:687-699.

(4.) Belgorosky A, Guercio G, Pepe C, Saraco N, Rivarola MA. Genetic and clinical spectrum of aromatase deficiency in infancy, childhood and adolescence. Hormone Research 2009;72:321-330. Epub 2009 Oct 21

(5.) Jones ME, Boon WC, McInnes K, Maffei L, Carani C, Simpson ER. Recognizing rare disorders: aromatase deficiency. Nat Clin Pract Endocrinol Metab 2007;3:414-421.

(6.) Harada N, Ogawa H, Shozu M, Yamada K. Genetic studies to characterize the origin of the mutation in placental aromatase deficiency Am J Hum Genet 1992;51:666-672.

(7.) Conte FA, Grumbach MM, Ito Y, Fisher CR, Simpson ER. A syndrome of female pseudohermaphrodism, hypergonadotropic hypogonadism, and multicystic ovaries associated with missense mutations in the gene encoding aromatase (P450arom). J Clin Endocrinol Metab 1994;78:1287-1292.

(8.) Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 1995;80:3689-3698.

(9.) Mullis PE, Yoshimura N, Kuhlmann B, Lippuner K, Jaeger P Harada H. Aromatase deficiency in a female who is compound heterozygote for two new point mutations in the P450arom gene: impact of estrogens on hypergonadotropic hypogonadism, multicystic ovaries, and bone densitometry in childhood. J Clin Endocrinol Metab 1997;82:1739-1745.

(10.) Ludwig M, Beck A, Wickert L, Bolkenius U, Tittel B, Hinkel K, Bidlingmaier F. Female pseudohermaphroditism associated with a novel homozygous G-to-A (V370-to-M) substitution in the P-450 aromatase gene. J Pediatr Endocrinol Metab 1998;11:657-664.

(11.) Belgorosky A, Pepe C, Marino R, Guercio G, Saraco N, Vaiani E, Rivarola MA. Hypothalamic-Pituitary-Ovarian axis during infancy, early and late prepuberty in an aromatase- deficient girl who is a compound heterocygote for two new point mutations of the CYP19 gene. J Clin Endocrinol Metab 2003;88:5127-5131.

(12.) Lin L, Ercan O, Raza J, Burren CP Creighton SM, Auchus RJ, Dattani MT&Achermann JC. Variable phenotypes associated with aromatase (CYP19) insufficiency in humans. J Clin Endocrinol Metab 2007;92:982-990. Epub 2006 Dec 12

(13.) Pepe CM, Saraco NI, Baquedano MS, Guercio G, Vaiani E, Marino R, Pandey AV, Fluck CE, Rivarola MA, Belgorosky APepe C, Saraco, Baquedano S, Guercio G, Vaiani E, Marino R, Pandey AV, Fluck CE, Rivarola MA, Belgorosky A. The cytochrome P450 aromatase lacking exon 5 is associated with a phenotype of non-classic aromatase deficiency, and it iis also present in normal human steroidogenic tissues. Clin Endocrinol (Oxf) 2007;67:698-705. Epub 2007 Jul 2

(14.) Deladoey J, Fluck C, Bex M, Yoshimura N, Harada N, Mullis PE. Aromatase deficiency caused by a novel P450arom gene mutation: impact of absent estrogen production on serum gonadotropin concentration in a boy. J Clin Endocrinol Metab 1999;84:4050-4054.

(15.) Ito Y, Fisher CR, Conte FA, Grumbach MM, Simpson ER. Molecular basis of aromatase deficiency in an adult female with sexual infantilism and polycystic ovaries. Proc Natl Acad Sci USA 1993;90:11673-11677.

(16.) Lee SJ, Kim WY, Choi JY, Lee SS, Shin JG. Identification of CYP19A1 single-nucleotide polymorphisms and their haplotype distributions in a Korean population. J Hum Genet 2010;55:189-193. Epub 2010 Feb 26

(17.) Gagliardi L, Scott HS, Feng J, Torpy DJ. A case of aromatase deficiency due to a novel CYP19A1 mutation. BMC Endocr Disord 2014;19:14-16.

(18.) Britt KL, Drummond AE, Cox VA, Dyson M, Wreford NG, Jones ME, Simpson ER, Findlay JK. An age-related ovarian phenotype in mice with targeted disruption of the Cyp19 (aromatase) gene. Endocrinol 2000;141:2614-2623.

Sema Akgurin (1), Doga Turkkahraman (2), Woo-Young Kim (3), Erdem Durmaz (4), Jae-Gook Shin (3), Su-Jun Lee (3)

(1) Akdeniz University Faculty of Medicine Hospital, Department of Pediatric Endocrinology, Antalya, Turkey

(2) Antalya Training and Research Hospital, Clinic of Pediatric Endocrinology, Antalya, Turkey

(3) Inje University College of Medicine, Department of Pharmacology, Inje University, Busan, Korea

(4) Izmir University Faculty of Medicine, Medical Park Hospital, Clinic of Pediatric Endocrinology, Izmir, Turkey

Address for Correspondence

Su-Jun Lee PhD, Inje University College of Medicine, Department of Pharmacology, Inje University, Busan, Korea

Phone: 82 51 890 86 65 E-mail:

[c]Journal of Clinical Research in Pediatric Endocrinology, Published by Galenos Publishing.

Conflict of interest: None declared

Received: 23.12.2015

Accepted: 23.01.2016

DOI: 10.4274/jcrpe.2761
Table 1. Laboratory values at diagnosis (a) and at last visitb

                    Case 1            Case 2          Case 3
                     a       b        a        b          a        b

Age (months)        <1       84      <1        60       <1        26
Na (mmol/L)        140      136     139       138      137       138
(Normal range:
K (mmol/L)           5        3.5     4         4.4      5.9       4.6
(Normal range:
LH (mIU/mL)         ND        0.1     1.9       1.9      ND        2.7
(Normal range:
FSH (mIU/mL)        ND        2.6     9.8      43.33     ND       49.1
(Normal range:
Estradiol (pg/mL)   ND       <5      16.4      <5        ND       15.4
(Normal range:
(ng/mL)              2.0      0.03    2.6       0.02     1.63      0.02
(Normal range:
ACTH (pg/mL)        25.1      4.1    16.9      23.22    28        60.1
(Normal range:
([micro]g/dL)       12.3      7.7     9.2      10.77     9.5      12.5
(Normal range:
(ng/mL)   7.5        0.45    25.0     0.87      9.8      0.15
(Normal range:
(ng/mL)              1.10     0.28    5.72      0.3      1.28      0.30
(Normal range:
([micro]g/dL)       59.6     78.8    93.1      17.7     61.9      11
(Normal range:

Na: sodium, K: potassium, LH: luteinizing hormone, FSH:
follicle-stimulating hormone, ACTH: adrenocorticotropic hormone,
DHEA-S: dehydroepiandrosterone sulfate, ND: not determined

Table 2. CYP19A1 single-nucleotide polymorphisms in the subjects (n=8)

Site           Position (a)      Amino acid    Reference    Subject (n)
                                                            wt/wt (n)

Exon 1.6       -196A>C                         rs10459592       0
Exon 1.6       -77G>A                          rs4775936        0
Intron 2       IVS2-59 A>G                     rs3759811        0
Exon 3         240A>G            V80V          rs700518         0
Intron 4       IVS4+77 (TTTA)n                 rs57921193
               n=7                                              0
               n=8                                              0
               n=9                                              0
Exon 5         568Cins (b)       Frame shift                    0
Intron 5       IVS5-16 T>G                     rs4324076        0
Intron 6       IVS6+36 A>T                     rs1143704        0
Intron 6       IVS6-106 T>G                    rs2304463        0
Exon 7         790C>T            R264C         rs700519         7
Intron 7       IVS7-79 A>G                     rs2289105        0
3'-UTR         1531 C>T                        rs10046          0

Site           Subject (n)                           Frequency
               wt/mt (n)          mt/mt (n)           (%)

Exon 1.6           0                  8              100
Exon 1.6           0                  8              100
Intron 2           1                  7               93.8
Exon 3             1                  7               93.8
Intron 4
                   1                  0                6.3
                   4                  4               75
                   3                  0               18.8
Exon 5             5                  3               68.8
Intron 5           1                  7               93.8
Intron 6           1                  7               93.8
Intron 6           1                  7               93.8
Exon 7             1                  0                6.3
Intron 7           1                  7               93.8
3'-UTR             1                  7               93.8

(a) The reference sequence used was GenBank accession no. NC_000015.
Position is indicated with respect to the start codon ATG in CYP19A1
gene; the A in ATG is +1 and the next base toward to 5' is -1.
(b) New variant allele was identified in the present study. 3'-UTR, 3'
untranslated region. 5'-UTR, 5' untranslated region.
COPYRIGHT 2016 Galenos Yayinevi Tic. Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Original Article
Author:Akgurin, Sema; Turkkahraman, Doga; Kim, Woo-Young; Durmaz, Erdem; Shin, Jae-Gook; Lee, Su-Jun
Publication:Journal of Clinical Research in Pediatric Endocrinology
Article Type:Report
Geographic Code:7TURK
Date:Jun 1, 2016
Previous Article:Clinical and Genetic Characteristics, Management and Long-Term Follow-Up of Turkish Patients with Congenital Hyperinsulinism.
Next Article:Gonadotropin-Releasing Hormone Analogue Treatment in Females with Moderately Early Puberty: No Effect on Final Height.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |